Navigation Links
Halocarbon Announces Licensing Agreement with IBM
Date:9/19/2009

Halocarbon has long produced hexafluoroisopropanol (HFIP) and has now entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

River Edge, NJ (PRWEB) -- Halocarbon Products Corporation (www.halocarbon.com), a leading worldwide producer of specialty fluorochemicals, has entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

"Halocarbon has long produced hexafluoroisopropanol (HFIP) as a key component in the manufacture of the anesthetic sevoflurane," said Halocarbon CEO Peter Murin. "With this agreement, we can partner our fluorochemicals development and manufacturing expertise with IBM's leadership in developing advanced electronic materials such as photoresists."

"This agreement will allow us to leverage our HFIP business and provide reliable, regular, cost-effective, US-based production of advanced photoresist compounds," added Murin.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world's leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing, inhalation anesthetics and other specialty products. For more information, please contact the company at +1-201-262-8899 or at www.halocarbon.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/09/prweb2904564.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
2. AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US
3. LCA-Vision Announces CEO Resignation
4. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
5. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
6. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
7. Aethlon Medical, Inc. Announces Annual Meeting Results
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Martek Announces Addition to Its Board of Directors
10. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
11. BVGH Announces New Board Chair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... clinical trial sites and study participants truly unified. TrialKit, a native mobile app, ... CFR Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers ...
(Date:7/18/2017)... ... ... Blood centers traditionally see a dangerous drop of blood donations during the ... community blood centers as high schools are out and many frequent donors are on ... up with the South Texas Blood & Tissue Center (STBTC), a subsidiary ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... solutions, today announced safety software company AB Cube has joined its ... segment to advance technology innovation across life sciences and healthcare. Under the ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont Pioneer today announced ... website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is ... enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is building on its ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):